Navigation Links
SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre
Date:5/23/2013

Tucson, Ariz. (PRWEB) May 23, 2013

SynCardia Systems, Inc. (http://www.syncardia.com), manufacturer of the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that the Glasgow Science Centre in Scotland, which boasts more than 380,000 visitors annually, is featuring the SynCardia temporary Total Artificial Heart powered by the Freedom® portable driver as part of its $3 million Bodyworks Exhibition, one of the most advanced exhibitions of its kind.

“BodyWorks combines the latest technology with an excellent approach to story-telling to define and explain that most complex of entities, the human body,” said Dr. Stephen Breslin, chief executive of Glasgow Science Centre.

The “Heart Pod” featuring the SynCardia Total Artificial Heart powered by the Freedom portable driver is one of 115 interactive exhibits, research capsules and live laboratory experiences that explore the science of health and wellbeing in the 21st Century. In order to demonstrate the innovative engineering behind this life-saving technology, the museum fabricated a full-size, semi-transparent human torso, which includes the skeletal system and internal organs.

Other exhibits for adults and children include:

  • A virtual autopsy table, the only one of its kind in the United Kingdom
  • A giant “hamster wheel” which measures stamina
  • A “DNA disco” that explains genetic science in an entertaining way
  • Plastinated human tissue samples that explain the make-up of the body

The Centre, which is the biggest of its kind outside London, is an award-winning, independent educational charity. Last year, more than 477,000 people experienced the museum’s exhibits, with more than 388,892 admissions to the Centre itself, and another 88,141 people reached via programming brought directly to local schools and communities.

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,100 implants of the Total Artificial Heart, accounting for more than 300 patient years of life.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among “America’s Most Promising Companies”

In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10762567.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Nebraska Medical Center Implants States First SynCardia Total Artificial Heart
2. University of Kentucky Medical Center Transplants States 1st SynCardia Total Artificial Heart Patient
3. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
4. 2012 American Business Awards?Honors SynCardia with Two Gold Stevie® Awards
5. News Site Offers Total Coverage of Texas Biotech Industry, Says BioNews Texas Publisher
6. Total Knee Replacement May Be Delayed by Up To Ten Years with an Arthroscopic Knee Surgery Treatment Known as the “Package”
7. ORNL wins 9 R&D 100s, bringing total to 173
8. Slovenias 1st Total Artificial Heart Patient Discharged from UMC Ljubljana Using the Freedom® Portable Driver
9. Blueprint for an artificial brain
10. Taylor-Wharton Announces Release of New Toro Line of Animal Artificial Insemination Products
11. Artificial cornea gives the gift of vision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... India , Jan. 19, 2017  Market Research Future has ... Global Market for Liquid Biopsy is growing rapidly and expected to ... Market Highlights ... The Global Liquid Biopsy Market has been assessed as a ... growth figures and boom in the coming future. There has been ...
(Date:1/19/2017)... , Jan 19, 2017 Research and Markets ... has announced the addition of ... Material, Application - Forecast to 2025" report to their ... The report provides a detailed analysis on current and ... forecasts till 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , Jan. ... and Altimmune, Inc., a privately-held immunotherapeutics company targeting ... definitive agreement for the merger of PharmAthene and ... include Novartis Venture Fund, HealthCap, Truffle Capital and ... fully-integrated and diversified immunotherapeutics company with four clinical ...
(Date:1/19/2017)... ... January 18, 2017 , ... The ... (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, ... subject to the existing policy. AMIA recommended that NIH earmark funding for researchers ...
Breaking Biology Technology:
(Date:1/18/2017)... , Jan. 18, 2017 ... company that supports the entire spectrum of clinical ... been another record-breaking year for the organization in ... interest in MedNet,s eClinical products and services. The ... tremendous marketplace success of iMedNet ...
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
Breaking Biology News(10 mins):